Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients

Transplant International : Official Journal of the European Society for Organ Transplantation
J M KovarikP Amlot

Abstract

SDZ CHI 621 is a murine-human chimeric monoclonal antibody (mAb) to the interleukin-2 (IL-2) receptor (CD25) intended for prophylactic immunosuppression against acute rejection in the first several weeks following kidney transplantation. A multicentre, prospective, dose-finding study was conducted in 37 primary, mismatched cadaver kidney transplant patients to assess its tolerability, pharmacokinetics and immunodynamics. Successive cohorts of patients were stratified to receive total doses of 20, 30, 40 or 60 mg (n = 4, 4, 14, 15, respectively) administered as 15- or 20-mg intravenous infusions with the first dose given preoperatively and subsequent doses within the first 10 days posttransplant. Daily mAb serum concentrations were analysed by a radioimmunoassay method and the percentage of peripheral T-lymphocytes expressing CD25 from serial blood samples was determined by FACScan. Intravenous administrations were well tolerated. mAb concentration profiles exhibited a biphasic decline with an initial t1/2 of 14.4 +/- 14.2 h, terminal t1/2 of 13.4 +/- 6.0 days, distribution volume (Vss) of 6.9 +/- 3.31 and clearance of 17.4 +/- 7.8 ml/h. The concentration-effect (mAb-CD25) relationship indicated that mAb concentrations exceeding...Continue Reading

Citations

Mar 26, 2004·Transplantation Proceedings·K PraditpornsilpaK Tungsanga
Jul 17, 1998·Transplant International : Official Journal of the European Society for Organ Transplantation·K P PlatzP Neuhaus
Dec 8, 2006·Expert Opinion on Biological Therapy·Carlo B Ramirez, Ignazio R Marino
Sep 16, 2015·Transplant International : Official Journal of the European Society for Organ Transplantation·Gilles ThibaultYvon Lebranchu
Mar 9, 2011·European Journal of Clinical Investigation·Frank UlrichJohann Pratschke
Mar 10, 2001·Clinics in Liver Disease·D C CroninJ M Millis
Jun 7, 2016·Pharmacotherapy·Kathleen C CunninghamArjang Djamali
Jul 4, 2001·Transplantation·P A KeownJ F Baladi
Feb 28, 2002·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Yvon CalmusDaniele Girault
Sep 12, 2006·Transplant International : Official Journal of the European Society for Organ Transplantation·S BeaudreuilB Charpentier
Jul 16, 2003·PharmacoEconomics·Tomonori HasegawaSunao Miki
Sep 1, 2005·Expert Review of Clinical Immunology·Mark D Pescovitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
S P DunnJ Meligeni
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology
D W Holt, A Johnston
© 2021 Meta ULC. All rights reserved